Comparative Efficacy of Pioglitazone, Saroglitazar, and Silymarin on Biochemical and Histopathological Hepatic Outcomes in a Wistar Rat Model of Non-alcoholic Fatty Liver Disease and Their Correlation With Insulin Sensitivity
Saroglitazar demonstrated the most comprehensive protective effects against NAFLD progression, surpassing pioglitazone and silymarin in biochemical, histological, and insulin resistance parameters. Its dual PPAR‑α/γ activity may offer a more effective therapeutic approach, supporting further translational evaluation in NAFLD management.
Authors
- Ipshita Jain
- Rishi Pal
- Rajendra Nath
- Madhu Kumar
- Rakesh Dixit
Institutions
- King George's Medical University (IN)
Publication Details
- Journal
- Cureus
- Published
- 2026-02-14
- DOI
- https://doi.org/10.7759/cureus.103631
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00